

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

4,800

Open access books available

122,000

International authors and editors

135M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



Risk Factors for Ovarian Cancer

Marliyya S. Zayyan

Abstract

Ovarian cancers remain a perplexing group of diseases that continue to raise questions over their etiology and clinical behavior. They are the most fatal of gynecological cancers. Despite a global lifetime risk of only 1–2%, they contribute the highest mortality and the lowest 5-year (overall) survival rate of just 35%. The three broad histological groups: epithelial, sex cord-stromal and germ cell cancers have different biologic behavior and may constitute different clinical disease entities. Of the eight subtypes in the epithelial group, high-grade serous are universally the most common and have the worst prognosis. Globally making 65–85% of all ovarian cancers, most of the focus on risk factors has been directed on the epithelial group but the importance of other primary malignancies cannot be overemphasized as a step towards understanding their etiology and clinical behavior. The normal ovary has none of the epithelia that produce the range of epithelial ovarian cancers or there is an obvious premalignant stage, symptoms are very vague, screening and early diagnosis are difficult and indeed unrewarding. No specific etiology is known for any of the histologic groups. However, commonly mentioned risk factors like increasing age, genetics, nulliparity, prolonged infertility, use of fertility drugs, high animal fat, obesity, endometriosis, polycystic ovary syndrome, previous history of cancer, use of hormone replacement therapy, pelvic inflammatory disease and smoking may not apply to all the subtypes, while factors like increasing parity, breast feeding, use of oral contraceptive pills, hysterectomy, tubal ligation and use of antioxidants may differ in the degree of protection they provide. There may also be geographical and probably racial variations in the relevance of some of the risk factors. Thorough understanding of the predisposing and protective factors of the various histologic subtypes is an important step understanding the disease and therefore improving treatment outcome or providing effective prevention.

Keywords: risk factors, ovarian cancers, histologic subtypes, variation

1. Introduction

Ovarian cancer (OC) is an important public health problem with a lifetime risk of 1–2%. Recent estimates indicate that 295,414 cases are expected in 2018 with about 184,000 of victims dying from the disease [1]. This reflects an increase of over 54,000 cases in incidence and 32,000 cases in mortality compared with earlier figures [2, 3]. Public screening for ovarian cancer has been neither feasible nor beneficial due to a lack of most appropriate screening test for the range of malignancies produced by the ovary. Use of tumor markers is largely unreliable since different tumor markers are secreted by different histological varieties and up to 50% of early disease may be associated with insignificant rise of tumor markers [4, 5]. Besides tumor markers could be raised by non-malignant conditions as well

as other malignancies [6–8]. Cancers of the lung, pancreas, colorectal, breast and non-Hodgkin’s lymphomas are associated with a rise in CA125 [9, 10] which is also raised in benign conditions such as endometriosis, ovarian cyst, leiomyoma uteri and pelvic inflammatory disease [4, 8, 11]. Only 50% of early OC is associated with raised CA125 making it unreliable for early diagnosis. More than 75% of OC are diagnosed in late stages of disease [12–14] when prognosis is very poor. Screening did not reduce mortality in two large trials [12, 15].

The ovaries are totipotential in their ability to form wide histologic varieties of cancers with different biology, natural history and possibly mechanism of onset [16–18]. These heterogeneous tumors differ in their clinical behavior including response to treatment and prognosis. Knowledge of the cause or genesis of OCs is very scant and the available hypotheses do not explain observed disease phenomena [19, 20]. The uniqueness of OC in having no known premalignant stage, no reliable screening tool, very vague symptoms in early and advanced stages make identification of at risk group important for prevention, early diagnosis and possibly as a step towards defining its etiology.

The World Health Organization classifies ovarian cancers based on histologic origins of the cells, as epithelial, sex cord-stromal and germ cell tumors [16, 21] (**Table 1**). The epithelial ovarian cancers are made up of eight histologic subtypes with different cellular origin, pathogenesis, gene expression and response to treatment [13, 16, 17]. The most common type, serous cyst adenocarcinoma with two distinct subtypes may be arising from the fallopian tube epithelium. The high grade serous accounts for 85% of the epithelial ovarian cancers and up to 80% of

Histological
I. Epithelial tumors
A. Serous cyst adenocarcinoma
B. Mucinous Cyst adenocarcinoma
C. Endometrioid
D. Clear cell (mesonephroid)
E. Brenner’s
F. Mixed epithelial
G. Undifferentiated
H. Unclassified
II. Sex cord-stromal tumors
A. Granulosa
B. Androblastoma
C. Gynandroblastoma
D. Unclassified
III. Lipid cell tumors
IV. Germ cell tumors
A. Dysgerminoma
B. Endodermal sinus tumors
C. Polyembroyoma
D. Choriocarcinoma
E. Teratoma
F. Mixed tumors
V. Gonadoblastoma
VI. Soft tissues not specific to the ovary
VII. Unclassified
VIII. Metastatic

Table 1.
WHO histological classification for ovarian cancers.

ovarian cancers generally [22]. It is the most challenging in terms of treatment outcome. Mucinous adenocarcinomas have cells similar to the cervical epithelium, endometrioid cancer cells resemble the endometrium, while Brenners tumors have transitional epithelium akin to that of the bladder [19].

The fimbriated end of the fallopian tube has morphologic and molecular similarities with high grade serous ovarian cancers which also expresses TP53 signature suggesting that neoplastic process may be originating from tubal epithelium and shed into the ovary where aggressive neoplastic process proceeds [14, 19]. Low-grade serous ovarian cancers share similar histogenesis but progress through a separate pathway and has different prognosis [18, 23, 24]. It represents less than 5% of the epithelial cancer [25].

The sex cord-stromal tumors are a heterogeneous group, which include several histologic subtypes (**Table 1**). Apart from adult granulosa tumor that affects women in their fifth decade, sex cord-stromal tumors mainly affect women in the second or third decade of life and account for about 5% of malignancies in women 15–24 years [26]. Several subtypes are associated with genetic predisposition, including in patients with Peutz-Jeghers syndrome [27].

The germ cell tumors, which include dysgerminomas, immature teratoma, embryonal tumors and endodermal sinus tumors form only 1.5–5% of OC. Approximately one-third are dysgerminomas, another third immature teratomas and a further one-third include the rest three (embryonal tumors, endodermal sinus tumors, choriocarcinoma and mixed cell types) [19, 28]. Malignant germ cell tumors of the ovary may be developing through similar pathways with testicular germ cell tumors but the ovarian have greater histological complexity than most solid somatic tumors.

This diversity in genesis may partly explain the observed differences in clinical behavior.

2. Hypothesis for ovarian carcinogenesis

Development of OC has remained a mystery since hypotheses advanced do not convincingly explain the observed phenomena. It is important to explain how other surface epithelia form aggressive primary neoplasm in a separate organ.

The ‘incessant ovulation’ theory explains that repetitive ovulatory micro trauma to the ovarian surface in association with the tubal epithelium results in carcinogenesis through mistakes in repair of the damaged surface epithelium [29, 30]. While this hypothesis partly explain serous cystadenocarcinoma, it fails to explain other subtypes in the epithelial group and does not offer plausible explanation for the germ cell tumors and the sex cord-stromal tumors.

The pituitary “gonadotropin hypothesis” indicates that high levels of estrogens and gonadotropins such as luteinizing hormone and follicle-stimulating hormone would over stimulate the ovarian epithelium causing increased proliferation and subsequent malignant transformation [31, 32].

The “inflammation hypothesis” proposes that factors such as endometriosis, pelvic inflammatory disease and other inflammatory conditions may stimulate cancer formation [31, 33].

These theories have failed to provide plausible genesis for ovarian cancer therefore new hypothesis have been proposed [19, 34].

Understanding a clear etiology is far from site, a thorough global analysis of the risk factors of the disease may be a good starting point to unraveling the etiology and therefore an effective strategy towards disease control and prevention. It is however expected that the range of tumors may very well differ in risk factors and epidemiology.

3. Predisposing factors

Predisposing and protective factors for ovarian cancers vary according to histologic type [13, 18]. Although most studies concentrate on epithelial ovarian cancers, particularly serous cystadenocarcinoma, which tends to form the major global disease burden, risk factors to other histologic types are important prerequisite to their genesis and will be considered in this review.

4. Racial and geographical risk

Ovarian cancer is a cosmopolitan disease as it occurs in every geographical location and in every race [1, 30]. Epithelial ovarian cancer is the commonest subtype all around the world with high-grade serous accounting for 60–85% of cases [22, 35–38].

Highest incidence of OC is found among white females in Northern and Western Europe and in North America with age adjusted incidence exceeding 8.4/100,000 [1, 30]. Recent statistics from the US show a decline in incidence from 16.6/100,000 in 1985 to 11.8/100,000 in 2018 [39]. Incidence is also high in New Zealand and among Jewish women in Israel but low in Africa and Asia with estimated rates of <3/100,000 [37]. Japan, though reported to have low incidence is experiencing a rising trend in the disease of recent [40].

All regions of North America show higher incidence of invasive ovarian cancer among white women [41].

Within Europe too, there is difference in incidence and mortality across the region. Using WHO data base of 28 European countries from 1953 to 2000, Bray et al. reported Nordic countries, Austria, Germany and the United Kingdom to have the highest trend in the 1960s but the trend tended to decline over the recent years while Southern European countries showed an upward trend. Similarly, central and eastern European countries with hitherto low incidence are experiencing a rising over time [12, 35]. In the most recent 5-year period (2003–2007), the incidence of ovarian cancer was highest in Eastern/Southern Europe, followed by Northern Europe, and Western Europe [22]. Asian sub region reports lower rates than Europe and America [2, 3].

South Eastern Asia have highest rate in the subcontinent and Eastern Asia has the lowest rate.

Migration to areas of high risk increases the risk of disease therefore cultural and dietary factors may be responsible for the observed difference. Japanese immigrants to the US have equivalent risk as natives [42]. Racial variations in the incidence of ovarian cancer are best observed in the USA. Age adjusted incidence rate are higher in whites than in non-whites and Indians in the USA have lowest mortality from ovarian cancer. While Caucasian Americans have higher disease incidence, African-Americans have 1.3 times higher disease mortality and lower survival rates even with equal access to care [43]. They also experienced poorer 5-year survival rates irrespective of stage of diagnosis [44, 45].

From the Surveillance Epidemiology and End Result (SEER) database (1992–1998), AA experienced a fall in 5-year survival rates from 47.9 to 40.3%, while their Caucasian counterparts witnessed an improved survival from 40.7 to 45% in the same period. The observed disparities have been linked to interplay of socioeconomic, environmental, genetic and epigenetic factors [43].

Determining the incidence of ovarian cancer in four US populations of heterogeneous racial-ethnic composition, Weiss and Paterson found 19–42% lower incidence among Japanese, Chinese, Hispano and black women compared with white women [44]. The observed difference is primarily due to lower rates of serous and papillary tumors. Chinese women also had decreased incidence of mucinous

tumors, while Hispano and black women had lower incidence of endometrioid-clear cell tumors.

The incidence of non-epithelial cancers remains fairly constant between the races; especially germ cell tumors which has remained stable in incidence for three decades [44]. However, data from SEER suggest that the incidence of sex cord-stromal tumors is significantly lower among white women compared with black women (0.18 *vs.* 0.35 per 100,000 person years; relative risk, 0.53; 95% confidence interval (95% CI): 0.42–0.67) [46].

OC rates from Africa though reported to be low must be considered in the background of health circumstances in the region of lack of cancer registries, poor utilization of health facilities and rudimentary statistics.

Ovarian cancer is reported to be more common in developed countries than developing nations but over the last three decades, ovarian cancer incidence has remained stable in high-risk countries, while an increasing trend has been reported in low-risk countries.

5. Age as a risk factor

Increasing age is a risk factor for ovarian cancer which is generally considered a disease of the older women. Globally, the annual incidence regardless of age is 42 cases/100,000 women. Data from US SEER, ovarian cancer is rare before the age of 40 years and incidence rises steadily after the fifth decade to reach a peak at 80–84 years, when the age specific incidence is 61.3/100,000 women. More than half of cases of ovarian cancers are diagnosed in women over 65 year [47].

In the United States, the annual incidence is 61.3 per 100,000 for women aged 75 and 79 years.

In the UK, the overall incidence of a symptomatic ovarian cyst in a premenopausal female being malignant is approximately 1:1000 increasing to 3:1000 at the age of 50 years although 1000 women under the age of 50 years develop ovarian cancer annually in the UK [48–50]. Most diagnose are other histologic subtypes like borderline tumors and germ cell tumors. EOC are generally reported to be uncommon in young premenopausal women in the UK [50]. Women aged 65 years and above make 64% of mortality from OC [47, 50]. Young premenopausal women are more commonly affected by germ cell tumors and borderline tumors in most reports from European literature [35, 51].

Similarly, a meta-database analysis of 5055 ovarian cancer patients of 4 prospective phase III intergroup trials identified 294 (5.8%) patients under the age of 40 years from European studies. Young age appeared a strong independent protective on overall incidence of EOCs as well as prognostic factor for PFS and OS [52].

The issue of age and ovarian cancer diagnosis may however be different among non-Europeans races. Reports from India show much younger age affected than most European papers for EOC. Murtha et al. reported increased risk after 35 years with peak at ages of 55–64 years. Saini et al. have reported mean age of 55 years Basu et al. had 48.8 ± 11.2 years while Mondel had 48 years and Jindal et al. had a mean of 48 years. Malik from Pakistan found mean age for EOC to be 49.5 ± 13 years [53–57].

Mostafa et al. from Egypt reported a mean age of 47 years for epithelial ovarian cancers, with 1% of cases affecting women of 30 years and only 3% occurring in older women of 70 years [58].

From African subcontinent, findings contradict increasing age as a risk factor for EOC as reports show young premenopausal women to be mostly affected with serous cystadenocarcinoma, which is the most common histiotype. There is increasing report of rising incidence of ovarian cancer from Africa [38, 59–61].

Most reports suggest EOC to be the commonest but predominantly seen in young premenopausal, generally parous women [38, 60, 61].

A global report by the International Federation of Gynecology and Obstetrics (FIGO) has noted that the highest incidence of ovarian cancer was moving towards a younger age group, although the majority of patients with epithelial cancer were more than 50 years in age [38].

It is interesting that high grade serous cyst adenocarcinoma remains the commonest variety while literature from USA, Europe, Israel and Australia find it in older women above 65 years, in Asia, the Arab world and Africa, it is observed in young premenopausal women. Research for this important difference is worthwhile.

Early menarche is considered a weak predictor of ovarian cancer risk and women whose menarche was earlier than 12 years are at increased risk of epithelial tumors [62, 63]. Meta-analysis of 22 case-control studies and 5 cohort studies has reported a statistically significant inverse association between menarcheal age and ovarian cancer risk (RR = 0.85; 95% CI: 0.75–0.97) [62], but this association is most significant in invasive serous and borderline tumors. In this respect, 'incessant ovulation' theory as possible cause of tumor genesis provides plausible explanation [30, 34]. No association was found when menarche begins after age 16 years. Late menarche has not been shown to be protective [64].

Women who experience natural late menopause are at increased risk [13, 34, 65]. Odds ratios for late natural menopause were reported as low as 1.19 and as high as 1.25 (95% CI: 0.95–1.49) [65]. These findings may suggest that earlier menarcheal age and late natural menopause might increase risk of ovarian cancer by increasing a woman's lifetime number of ovulations. Results from the Nurses' Health Study (NHS) confirmed increased risk of endometrioid epithelial cancers with late natural menopause but not of serous or mucinous cancers (RR = 1.3, 95% CI: 1.04–1.22). Furthermore, the European Prospective Study into Cancer and Nutrition Cohort (EPIC) age at menopause >52 years was associated with increased risk compared with 45 years or less [66].

6. Infertility and use of ovulation induction drugs

Infertility either by itself or in association with some of its causes like endometriosis, is a risk factor and prolonged period of infertility is associated with higher risk [67].

A large cohort study, involving 54,362 women with infertility in the Danish fertility clinics (1963–1998) used parity specific cancer incidence and reported significantly increased from infertility (1.46, 95% CI: 1.24–1.71) [68].

Whittemore et al. analyzed 12 US case-control studies between 1957 and 1985, with 2197 cases of ovarian cancer and 4144 controls and confirmed higher risk in nulligravid subfertile women compared with controls [20].

However, study by Ness with 5207 cases of ovarian cancer and 7705 controls found only a weak association between infertility and epithelial ovarian cancer (OR 1.16, 95% CI: 1.02–1.31) [69].

Drug treatment of infertility may further increase risk as untreated infertile nulliparous women have 1.5–2-fold risk, while women who received treatment and failed to conceive have even higher risk [70].

Use of ovulation induction agents like clomiphene citrate, gonadotropins are associated with three times higher general population [69] particularly prolonged use of clomiphene (for more than 12 cycles). This is associated with rise in risk for invasive and borderline cases by about 11.1-fold compared with infertile women with no clomiphene use [67].

Use of gonadotropins is also associated with increased risk [31, 70]. There are, however, a number of studies that show no increased risk of OC with use of ovulation induction agents [71].

However, studies that report increased risk do of borderline tumors only not high grade serous.

7. Genetic factors

More than one-fifth of OC cases are hereditary from highly penetrant autosomal dominant genetic susceptibility [72]. Although accounting for only a limited number of cases, heredity is a strong risk factor for OC. The lifetime risk of a woman who has a first degree relative with OC is 5% compared with 1.4% in a woman without. The risk rises to 7% if two members of the family are affected [73]. These rate has been thought to be a probable underestimate as a British study has shown that where two close relatives (not necessarily first degree) are affected, the risk may be as high as 30–40% [73, 74]. The risk for confirmed carriers of BRCA at the age of 70 may be as high as 63% [73, 75]. Ovarian cancer in a first degree relative, has been shown to be a strong positive indicator of early onset epithelial cancer and positively associated with non-mucinous tumors [76].

The three main clinical types of genetic ovarian cancers include site-specific, hereditary breast and/or ovarian cancer (HBOC) and hereditary non-polyposis colorectal cancer (HNPCC) or Lynch II syndrome [77].

The first two syndromes are related to inheritance of BRCA1 and BRCA 2. Patients with HNPCC have inherited mismatch repair genes (MLH1, MLH2, MLH6, PMS1, PMS2 and possibly some other yet unidentified genes).

BRCA genes are common in the Ashkenazi Jewish population where 29–41% of ovarian cancer is believed to be secondary to inheriting one of three founder mutations in *BRCA1* and *BRCA2*, against 10% in non-Ashkenazim [78].

BRCA 1 gene is an oncosuppressor gene located at chromosome 17q, it participates in chromatin remodeling and crucial steps in cell cycle [79].

OC associated with BRCA mutations are diagnosed at a younger age and are of high-grade serous type. In one study, the average age at diagnosis of OC in BRCA1 and BRCA2 mutation carriers was 52 and 62 years, respectively [77, 80]. BRCA mutations do not seem to play a significant role in the development of mucinous or borderline ovarian tumors. The BRCA associated OCs also tend to have better clinical outcome with longer overall survival and recurrence-free interval than sporadic cancers [77].

There is no standard clinical definition of hereditary breast and ovarian cancer syndrome but affected families may be identified from:

- Several cases of breast cancer diagnosed before the age of 50 years.
- One or more cases with ovarian cancer in the family.
- One or more relatives with both breast and ovarian cancer.
- The presence of a BRCA1 or BRCA 2.
- However, many women without a family history may still have a gene mutation associated with their BRCA1 or BRCA 2.

Lynch syndrome (LS) or hereditary non-polyposis colon cancer (HNPCC) refers to germline mutations in MMR genes (*MLH1*, *MSH2*, *MSH6*, *MLH3* and *PMS2*),

which lead to the loss of expression of one of the MMR proteins. Clinically, LS is associated with higher risk of colorectal cancers that have specific predilection to location proximal to splenic flexure [72, 81]. Confirmed case of Lynch syndrome is associated with 6–10% life time risk of OC of early onset. MLH1 carriers are often diagnosed of ovarian cancer at average age of 52 years and MLH2 carriers at age of 45 years [82, 83].

HNPCC syndrome is also associated with cancers of the stomach, small bowel, hepatobiliary tract, pancreas, renal pelvis, ureter, breast, prostate and brain (particularly glioblastoma) [72, 84]. The OCs associated with LS are commonly endometrioid and clear cell varieties [82, 85] and tend to be diagnosed at a relatively early stage with high stage-specific survival rate compared with non LS type [86, 87].

The Li-Fraumeni syndrome is an autosomal dominant syndrome characterized by heterozygous germline mutation in TP53. It is the most frequently mutated gene in human cancer thus the syndrome is associated with development of multiple cancers at young age. About 50% will develop first tumor at age of 30 years [88] and up to 35% will develop multiple tumors in their lifetime [89]. Li-Fraumeni syndrome associated OC, though not the most common but tend to occur at around 39.5 years [90].

Peutz-Jeghers syndrome (PJS) is a rare autosomal dominant condition occurring in 1 in 25,000–30,000 livebirths [91] characterized by benign hamartomatous intestinal polyps with very low tendency to malignancy, cutaneous lesions increased risk of OC in addition to cancers of breast, colon, rectum, pancreas, stomach, testicles and lungs. Tumor suppressor gene STK11 (LKB1), located on chromosome 19p13.3 is responsible for this syndrome. OC risk is as high as 18–21% [92]. The ovarian cancers associated with this syndrome are sex cord tumor with annular tubules (SCTATs) in addition to a range of other gynecological cancers [92, 93].

Mutations in double strand breaks repair system like *CHEK2*, *RAD51*, *BRIP1* and *PALB2* are also associated with increased risk of various types of ovarian cancer [89, 94]. To date, more than 16 genes are known to be involved in the mechanism of hereditary ovarian tumorigenesis and new ones are being discovered [77, 95].

8. Use of perineal talc

Talc, a metamorphic mineral composed of silicon, magnesium and oxygen, is a common component of genital powders. Applied by women for moisture absorption to prevent perineal chafing and rashes, talc has similarities to and co-occurs with asbestos in its natural form, which is a known carcinogen [96, 97]. Contamination of talc with asbestos was hypothesized to have a causal role in ovarian carcinogenesis [13, 98]. The finding of talc materials in ovarian cancer specimens supports this argument [99]. The International Agency for Research on Cancer (IARC) in 2006, classified genital talc use as possibly carcinogenic to humans based on evidence from epidemiologic studies (carcinogen group 2B) [100, 101].

Although the biological basis of talc carcinogenicity is not clear, direct physical contact with ovarian epithelium may cause chronic inflammation and retrograde transport of talc particles through the reproductive tract as suggested by some workers may occur [98]. An immune mechanism may also be the case.

Several case-control studies report association between perineal talc use and ovarian cancer and data from Women Health Initiative support this association also support this fact [98, 102–104]. Furthermore, a prospective study has confirmed association with serous cystadenocarcinoma and talc use. However asbestos-free talc has been in use in cosmetic products at least in most developed countries and later case-control studies show no association between use of talc and ovarian cancer [104]. Other case-control studies found increased risk by 92% that is a relative risk of 1.92 [98]. A study by Cook et al. reported 1.60 relative risk of ovarian cancer with use than non-use. This is an increase of 60%. Finally, a meta-analysis of about 20 published

works reported 35% increased risk of cancer in women who used talc [102]. Scientific evidence has weighed heavily against the makers of talc products who recently lost over 4 billion dollars to a group of 22 women who developed ovarian cancer following talc use adding a court evidence to ovarian carcinogenesis by talc [105].

9. Diet and ovarian cancer

Diet has been directly or indirectly related to risk of ovarian cancer though very few studies specify the histologic subtype in relation to dietary types. Diet may be modifying the risk of ovarian cancer through effect on endogenous hormones, antioxidant activity or other anticarcinogenic mechanisms. There is however a unanimous finding of reduced incidence of ovarian cancer with higher intake of vegetables especially for epithelial ovarian cancer [106–111]. The average finding is a reduction of risk by about more than 50%. High dietary fiber, carotenoids total ligands and phytochemicals are associated with reduced risk [112].

Dairy products have received conflicting results. While over the years, studies showed no associations between dairy intake and ovarian cancer of any type [113, 114]. Faber et al. using the Danish population-based case–control studies reported increased risk especially with milk and lactose but decreased risk with cheese [115]. An interesting study by Merritt et al. using data from New England case–control study examined including histological subtypes and tumor aggression in relation to intake of dairy foods. They reported decreased risk of serous borderline and mucinous cancer with higher intake of calcium and vitamin D. High Vitamin D intake was also found to be inversely related to serous borderline and endometrioid cancers [116]. Merritt et al. found no evidence between lactose intake and risk of ovarian cancer [116].

High intake of total fat, animal fat, cholesterol and saturated fats may be associated with increased risk. Meta-analysis of 16 independent studies reported significant increase in risk of ovarian cancer with high intake of total saturated and trans fats with serous cancers being especially susceptible to dietary fats than other histologic subtypes [117, 118]. Huncharek and Kupelnick reported a RR of 1.70 or an increased risk of 70% in patients with high fat intake [117], however Bertone et al. found no association with intake of fats alone but associated increased with when combined with high intake of eggs [119]. High intake of eggs alone are reported to increase risk [111, 120]. This effect has been linked to high dietary cholesterol which may be increasing risk of ovarian cancer through increased circulating estrogens [111, 121].

Although the link between ovarian cancer and high intake of meat has been controversial with some studies finding no association [122], majority report positive association between high intake of red and processed meat with epithelial ovarian cancer, while poultry and fish have either no relative increase or observed reduction in risk [123–126].

High alcohol consumption has been studied in reasonable depth and only few studies show no association [127] while others show a reduction in risk with minimal and moderate intake of alcohol [128, 129]. The observed phenomenon may be due to the anti-oxidants in the wine and alcohol rather than the alcohol itself [130]. While tea consumption has not been associated with risk of ovarian cancer, coffee is associated with modest reduction of risk [131, 132].

High dietary intake of B carotene is reported to be protective against epithelial ovarian cancer; in a meta-analysis of over 3782 subjects, a modest 16% reduced risk was found [133]. Supplemental selenium (>20 µg daily) is associated with 30% risk reduction [134]. This fact, however, does not support use of selenium as a preventive strategy [135]. These antioxidants may be reducing risk by limiting oxidative stress to the ovarian epithelium.

The effect of vitamin D, particularly D3, has been of interest because of its ability to cause apoptosis of cancer cells in vitro and the demonstrated increased risk of ovarian cancer in vitamin D deficient Europeans [136], more research is necessary to define clinical implication of these findings as some researchers propose supplementation of vitamin D for preventive purposes [137].

10. Smoking

Association between cigarette smoking and ovarian cancer is not as clear as other cancers like lungs oropharynx and lungs that are very well documented [138]. However, metabolites of nicotine which are potent hydrocarbons and carcinogens like cotidine and benzopyrene have been isolated in follicular fluid and OC has been induced in rodents with cyclical hydrocarbons [139].

Cigarette smoking is associated with increased risk of mucinous ovarian cancers [140–143] but the effects on other histologic types is less clear. A Norwegian study, found increased risk of invasive borderline cancers in addition to mucinous [140]. Smokers however have a deficit of endometrioid tumors.

Survival of patients who smoke is also found to be worse than that of non-smokers [142, 144]. Studies have confirmed the increased risk of mucinous epithelial cancers in smokers to be directly proportional to the pack-years of smoking [145, 146]. A twofold increased risk of mucinous epithelial cancers is the generally observed phenomenon [141, 143, 146], but could be up to fourfold increase in women who have smoked for 40 years or more [146].

There is a suggestion however that with the deficit in clear cell and endometrioid cancer and despite the increase in borderline and mucinous cancer smoking may not be associated with overall increase in ovarian cancer mortality [144].

11. Endometriosis and risk of ovarian cancer

OC prevalence in women with endometriosis is higher than the general population 1.32–1.9 [147]. A recent systemic review agrees with this modest increase in risk of endometrioid, borderline and clear cell cancers with endometriosis [148]. Some reports suggest about two to threefold increase in risk [149]. This association between endometriosis and OC is not a proof of causality for the histiotypes.

It is more common in patients with longstanding or recurrent endometriosis and removal of endometrioma is not preventive towards development of OC [150]. The increased risk might be due to high estrogen concentration or due to gene mutations caused by oxidative stress due to iron in the endometriotic cyst [151].

12. Polycystic ovarian syndrome

PCOS is the commonest endocrine disease in women of reproductive age with incidence of about 20% [152]. Associated with infertility, obesity and abnormal gonadotropin secretion, PCOS is associated with 2.5-fold increased risk of epithelial ovarian cancer [153]. The risk of ovarian cancer in women with PCOS is greatest in lean women and those who never used oral contraceptive pills [153, 154].

A systemic review involving eight studies and a meta-analysis found increased incidence of borderline serous cancer in patients with PCOS [155]. Proteomic biomarkers for identification of patients with PCOS who are at increased risk of ovarian cancer may be useful for early diagnosis but the clinical use of these markers need further verification [156].

13. Pelvic inflammatory disease

Inflammation has been implicated in ovarian carcinogenesis but studies investigating the association between pelvic inflammatory disease (PID) and ovarian cancer risk are few and inconsistent with some studies reporting positive association [157, 158] and others excluding such association [159, 160]. A pooled reanalysis of 13 studies reported increased risk of borderline ovarian tumors in women who had multiple episodes of pelvic inflammation [157]. This association may be pronounced among Asian women [158]. Rasmussen et al. in a population-based cohort study recently reported increase in risk of serous ovarian cancer in patients with PID [157]. Therefore we can conclude that repeated episodes of PID is associated with statistically significant risk of borderline and serous cancers but not non-epithelial cancers which have been found not to be associated with PID [158].

14. Hormone replacement therapy (Hrt) and risk of ovarian cancer

Women who use menopausal hormone therapy are at an increased risk for ovarian cancer. A review and meta-analysis of data published between 1966 and 2006 concluded that current use of postmenopausal hormone therapy (HT) increased the risk of ovarian cancer by 30% compared with never use of HT [161]. Estrogen alone was thought to confer higher risk than combined estrogen and progesterone which is refuted by finding from data from million women study [162, 163]. Recent studies indicate that using a combination of estrogen and progestin for 5 or more years significantly increases the risk of serous and endometrioid OC in women with intact uterus, but for women who have had hysterectomy, 10 or more years of use is associated with increased risk [161, 164, 165]. In a recent pooled analysis of 52 epidemiological studies, the risk of serous cancer was 51.4% and that of endometrioid was 48.6% [164]. The increase has been interpreted to mean one extra OC in 1000 users and one extra mortality in 1700 user [166]. There is more risk with prolonged use irrespective of the type of HRT, regimes used or mode of administration.

15. Obesity

Obesity may be increasing risk of ovarian cancer significantly [166–168]. Obese women ($\text{BMI} > 30 \text{ kg/m}^2$) who have not used menopausal hormone replacement therapy (MHR) had 25–80% increased risk compared with women with normal BMI (18.5–24.9) no relationship between BMI and OC in women with family history. Obesity is associated with an almost 80% higher risk of ovarian cancer in women 50–71 who had not taken hormones after menopause. For women who have not used HRT, evidence shows risk of ovarian cancer to increase by 10% with every 5 kg/m^2 increase in BMI (Collaborative Study). Higher BMI in young adulthood is reported to increase risk of premenopausal ovarian cancers [167].

Evidence from meta-analysis of 14 studies shows that slightly worse survival in obese women with ovarian cancer compared to non-obese women (pooled HR = 1.17, 95% CI: 1.03–1.32) [169].

Obesity may be increasing this risk for ovarian cancer through increasing inflammatory biomarkers and increase in hormonal factors especially androgens which is important in development of mucinous tumors [170].

Histologic subtypes associated with obesity include low-grade serous, mucinous tumors and endometrioid cancers. No association was found between high grade serous and obesity therefore reducing BMI is unlikely to reduce the incidence of

high grade serous cancers [171]. Moreover, obese women with HGSC have poorer outcome than their non-obese counterparts [172].

Recent systemic review of 43 studies involving more than 3 million women concludes that the evidence is inconsistent that obesity is a definite risk factor for ovarian cancer [173]. This finding may be due to the dominance of HGSC which risk is not affected by obesity.

16. Protective factors that reduce risk of ovarian cancer.

16.1 Pregnancy

Pregnancy is thought to be protective against ovarian cancer [13, 47, 65]. Pregnancy whether uncompleted or term confers a protective benefit against epithelial ovarian cancer. Increasing parity is associated with a reduction in the risk of ovarian cancer [36, 63, 65, 174]. Pregnancy may be protective against all histological subtypes. A Swedish study has reported reduced risk for epithelial, stromal and germ cell tumors, but less consistent decrease in borderline cancers [63].

However, it appears that the protective effect of pregnancy (and breast feeding) so called reproductive factors, may be more significant in the West, parts of the US and among Jewish women as reports of ovarian cancer of all histologic subtypes in parous women in developing countries is so widespread and requires further research [38, 53, 55, 57, 59, 60]. The significance of this phenomenon is that the protective effect of pregnancy may be lost in the face of other more important risk factors that need to be defined.

All theories of ovarian carcinogenesis are not plausible explanation for the observed protective effect of pregnancy, therefore pregnancy-induced clearance of malignant cells has been proposed [63] which must to be case in all races to be an acceptable hypothesis.

16.2 Breastfeeding

Breast feeding exerts a strong protective effect with long-term breast feeding being more protective especially against epithelial cancers [175]. The mechanism may be by suppression of gonadotropins through unovulation, resulting in depressed production of plasma estradiol and unovulatory cycles [65, 176]. Breastfeeding also reduces the levels of gonadotropins, especially luteinizing hormone [176], which may be causal mechanism for ovarian carcinogenesis [177].

Meta-analysis of 12 US studies and 9 studies from developed countries showed an inverse association between breastfeeding and ovarian cancer risk [175]. Women who breast fed for up to 6 months showed duration-dependent benefit with women who breastfed for long having more protection. Breast feeding may be reducing risk of epithelial cancers by up to 30% compared with women who did not breast feed.

16.3 Oral contraceptives

The use of oral contraceptives decreases the risk of developing OC and the benefit may be enjoyed up to 25–30 years after stopping the pill [178, 179]. COCP use is associated with about a 40–50% lower risk compared with never use [178, 180]. Length of pill use appears to influence the degree of protection, with a relative risk of 0.4 for more than 5 years reported in pooled European and US studies [178, 181].

The protective benefit may be experienced even in high risk women though there is not enough evidence for use of the pill for chemoprophylaxis [180, 182, 183]. Women who use the pills for more than 5 years enjoy more protection of about 50% reduction [179]. This protection is enjoyed by women of all ages and parities.

Therefore while HRT is associated with increasing risk, the pills are associated with reduced risk a position both have similar active ingredients and estrogen has been blamed in ovarian carcinogenesis.

16.4 Hysterectomy/tubal ligation

Observational epidemiologic evidence strongly support tubal ligation and hysterectomy to be associated with a decrease in the risk of ovarian cancer, by approximately 26–30% [184]. Having fallopian tubes tied hysterectomy and unilateral oophorectomy may reduce risk by up to 67% [184, 185].

Patients with BRCA1 but not with BRCA2 are found to benefit from the protection conferred by tubal ligation to OC [186]. Tubal ligation and hysterectomy reduce risk of low grade more than high grade serous cancers. Risk of endometrioid cancer is almost halved. Tubal ligation is not observed to reduce the risk of mucinous tumors [187].

16.5 Physical activity and exercise

Physical activity may be beneficial in both risk reduction of inflammation, decreasing body fat and frequency of ovulation. Survivors of ovarian cancer may also experience general health benefit of physical activity [188]. The specific effect of physical exercise on ovarian cancer in general and the various histologic subtypes have shown inconsistent results. The most consistent result obtained by research is that of increasing risk by prolonged sedentary life style physical inactivity [188, 189].

Considering direct effect of physical activity however, some studies report no effect on the risk of ovarian cancer [190, 191] while other studies report risk reduction [190, 191]. The reduction of risk may be to epithelial cancers. Physical activity may not be affecting sex cord-stromal and germ cell cancers of the ovary.

17. Conclusion


The risk of ovarian cancer in women is modified by a number of biologic, hormonal, lifestyle and geographic factors the extent of which differs between the histologic varieties. There may be racial or regional variation in the extent to which these factor increase risk or protect against particularly the most common histologic subtype.

Author details

Marliyya S. Zayyan
Oncology Department of Obstetrics and Gynecology, Ahmadu Bello University,
Zaria, Nigeria

*Address all correspondence to: marliyya.zayyan@gmail.com

IntechOpen

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 

References

- [1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*. n.d. DOI: 10.3322/caac.21492
- [2] Jacques F, Isabelle S, Rajesh D, Sultan E, Colin M, Marise R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *International Journal of Cancer*. 2014;**136**:E359-E386. DOI: 10.1002/ijc.29210
- [3] Malvezzi M, Carioli G, Rodriguez T, Negri E, La Vecchia C. Global trends and predictions in ovarian cancer mortality. 2016;**27**. DOI: 10.1093/annonc/mdw306
- [4] Kumar B, Davies-Humphreys J. Tumour markers and ovarian cancer screening. *The Obstetrician and Gynaecologist*. 2011;**2**:41-44. DOI: 10.1576/toag.2000.2.4.41
- [5] Alberico S, Facca MC, Millo R, Radillo L, Mandruzzato GP. Tumoral markers (CA 125--CEA) in the screening of ovarian cancer. *European Journal of Gynaecological Oncology*. 1988;**9**:485-489
- [6] Bairey O, Blickstein D, Stark P, Prokocimer M, Nativ HM, Kirgner I, et al. Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma. *Leukemia and Lymphoma*. 2003;**44**:1733-1738. DOI: 10.1080/1042819031000104079
- [7] Fritsche HA, Bast RC. CA 125 in ovarian cancer: Advances and controversy. *Clinical Chemistry*. 1998;**44**:1379-1380
- [8] Pepin K, del Carmen M, Brown A, Dizon DS. CA 125 and epithelial ovarian cancer: Role in screening, diagnosis, and surveillance. *Journal of Hematology and Oncology*. 2014;**10**
- [9] Eagle K, Ledermann JA. Tumor markers in ovarian malignancies. *The Oncologist*. 1997;**2**:324-329
- [10] Berek JS, Bast RC. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. *Cancer*. 1995;**76**:2092-2096
- [11] Bast RC. Status of tumor markers in ovarian cancer screening. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 2003;**21**:200s-205s. DOI: 10.1200/JCO.2003.01.068
- [12] La Vecchia C. Ovarian cancer: Epidemiology and risk factors. *European Journal of Cancer Prevention*. 2017;**26**:55-62. DOI: 10.1097/CEJ.0000000000000217
- [13] Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: A review. *Cancer Biology and Medicine*. 2017;**14**:9-32
- [14] Holschneider CH, Berek JS. Ovarian cancer: Epidemiology, biology, and prognostic factors. *Seminars in Surgical Oncology*. 2000;**19**:3-10. DOI: 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S
- [15] Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK collaborative trial of ovarian cancer screening (UKCTOCS): A randomised controlled trial. *Lancet (London, England)*. 2016;**387**:945-956. DOI: 10.1016/S0140-6736(15)01224-6
- [16] Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, et al. The new WHO

classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. *Archives of Gynecology and Obstetrics*. 2016;**293**:695-700. DOI: 10.1007/s00404-016-4035-8

[17] Prat J, D'Angelo E, Espinosa I. Ovarian carcinomas: At least five different diseases with distinct histological features and molecular genetics. *Human Pathology*. 2018;**80**:11-27. DOI: 10.1016/j.humpath.2018.06.018

[18] A Soslow R. Histologic subtypes of ovarian carcinoma: An overview. *International Journal of Gynecological Pathology*. 2008;**27**:161-174. DOI: 10.1097/PGP.0b013e31815ea812

[19] Kurman R, Shih I-M. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. *The American Journal of Surgical Pathology*. 2010;**34**:433-443. DOI: 10.1097/PAS.0b013e3181cf3d79

[20] Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. *The American Journal of Epidemiology*. 1992;**136**:1212-1220

[21] WHO classification of ovarian neoplasms n.d. Available from: <http://www.pathologyoutlines.com/topic/ovarytumorwhoclassif.html> [Accessed: 16 September 2018]

[22] Coburn SB, Bray F, Sherman ME, Trabert B. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. *International Journal of Cancer*. 2017;**140**:2451-2460. DOI: 10.1002/ijc.30676

[23] Ahn G, Folkins AK, McKenney JK, Longacre TA. Low-grade

serous carcinoma of the ovary: Clinicopathologic analysis of 52 invasive cases and identification of a possible noninvasive intermediate lesion. *The American Journal of Surgical Pathology*. 2016;**40**:1165-1176. DOI: 10.1097/PAS.0000000000000693

[24] Vang R, Shih I-M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: Pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. *Advances in Anatomic Pathology*. 2009;**16**:267-282. DOI: 10.1097/PAP.0b013e3181b4fffa

[25] Lalwani N, Prasad SR, Vikram R, Shanbhogue AK, Huettner PC, Fasih N. Histologic, molecular, and cytogenetic features of ovarian cancers: Implications for diagnosis and treatment. *Radiographics*. 2011;**31**:625-646. DOI: 10.1148/rg.313105066

[26] Schultz KAP, Harris AK, Schneider DT, Young RH, Brown J, Gershenson DM, et al. Ovarian sex cord-stromal tumors. *Journal of Oncology Practice/American Society of Clinical Oncology*. 2016;**12**:940-946. DOI: 10.1200/JOP.2016.016261

[27] Boyd J. Specific keynote: Hereditary ovarian cancer: What we know. *Gynecologic Oncology*. 2003;**88**:S8-S10; discussion S11-13

[28] Low JJH, Ilancheran A, Ng JS. Malignant ovarian germ-cell tumours. *Best Practice and Research. Clinical Obstetrics and Gynaecology*. 2012;**26**:347-355. DOI: 10.1016/j.bpobgyn.2012.01.002

[29] Fathalla MF. Incessant ovulation—A factor in ovarian neoplasia? *Lancet (London, England)*. 1971;**2**:163

[30] Fathalla MF. Incessant ovulation and ovarian cancer—A hypothesis re-visited. *Facts Views Vis ObGyn*. 2013;**5**:292-297

- [31] Choi J-H, Wong AST, Huang H-F, PCK L. Gonadotropins and ovarian cancer. *Endocrine Reviews*. 2007;**28**:440-461. DOI: 10.1210/er.2006-0036
- [32] Lee AW, Tyrer JP, Doherty JA, Stram DA, Kupryjanczyk J, Dansonka-Mieszkowska A, et al. Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. *Gynecologic Oncology*. 2015;**136**:542-548. DOI: 10.1016/j.ygyno.2014.12.017
- [33] Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. *Journal of the National Cancer Institute*. 1999;**91**:1459-1467. DOI: 10.1093/jnci/91.17.1459
- [34] Purdie DM, Bain CJ, Siskind V, Webb PM, Green AC. Ovulation and risk of epithelial ovarian cancer. *International Journal of Cancer*. 2003;**104**:228-232. DOI: 10.1002/ijc.10927
- [35] Bray F, Loos AH, Tognazzo S, La Vecchia C. Ovarian cancer in Europe: Cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. *International Journal of Cancer*. 2005;**113**:977-990. DOI: 10.1002/ijc.20649
- [36] Albrektsen G, Heuch I, Kvåle G. Reproductive factors and incidence of epithelial ovarian cancer: A Norwegian prospective study. *Cancer Causes and Control*. 1996;**7**:421-427. DOI: 10.1007/BF00052668
- [37] Keinan-Boker L, Silverman BG, Walsh PM, Gavin AT, Hayes C. Time trends in the incidence and mortality of ovarian cancer in Ireland, Northern Ireland, and Israel, 1994-2013. *International Journal of Gynecological Cancer*. 2017;**27**:1628-1636. DOI: 10.1097/IGC.0000000000001079
- [38] Iyoke C, Ugwu G, Ezugwu E, Onah N, Ugwu O, Okafor O. Incidence, pattern and management of ovarian cancer at a tertiary medical center in Enugu, south East Nigeria. *Annals of Medical and Health Sciences Research*. 2013;**3**:417-421. DOI: 10.4103/2141-9248.117947
- [39] Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. *CA: A Cancer Journal for Clinicians*. 2018;**68**:284-296. DOI: 10.3322/caac.21456
- [40] Yamagami W, Nagase S, Takahashi F, Ino K, Hachisuga T, Aoki D, et al. Clinical statistics of gynecologic cancers in Japan. *Journal of Gynecologic Oncology*. 2017;**28**:e32. DOI: 10.3802/jgo.2017.28.e32
- [41] Goodman MT, Howe HL, Tung KH, Hotes J, Miller BA, Coughlin SS, et al. Incidence of ovarian cancer by race and ethnicity in the United States, 1992-1997. *Cancer*. 2003;**97**:2676-2685. DOI: 10.1002/cncr.11349
- [42] Weiderpass E, Sandin S, Inoue M, Shimazu T, Iwasaki M, Sasazuki S, et al. Risk factors for epithelial ovarian cancer in Japan—Results from the Japan public health center-based prospective study cohort. *International Journal of Oncology*. 2012;**40**:21-30. DOI: 10.3892/ijo.2011.1194
- [43] Srivastava A, McKinnon W, Wood ME. Risk of breast and ovarian cancer in women with strong family histories. *Oncology Williston Park N*. 2001;**15**:889-902; discussion 902, 905-7, 911-3
- [44] Weiss NS, Peterson AS. Racial variation in the incidence of ovarian cancer in the United States. *American Journal of Epidemiology*. 1978;**107**:91-95. DOI: 10.1093/oxfordjournals.aje.a112522
- [45] Stewart SL, Harewood R, Matz M, Rim SH, Sabatino SA, Ward KC, et al.

Disparities in ovarian cancer survival in the United States (2001-2009): Findings from the CONCORD-2 study. *Cancer*. 2017;**123**(Suppl 24):5138-5159. DOI: 10.1002/cncr.31027

[46] SEER Cancer Statistics Review 1973-1997—Previous Version—SEER Cancer Statistics n.d. Available from: https://seer.cancer.gov/archive/csr/1973_1997/ [Accessed: 02 August 2018]

[47] Doufekas K, Olaitan A. Clinical epidemiology of epithelial ovarian cancer in the UK. *International Journal of Women's Health*. 2014;**6**:537-545. DOI: 10.2147/IJWH.S40894

[48] Morowitz M, Huff D, von Allmen D. Epithelial ovarian tumors in children: A retrospective analysis. *Journal of Pediatric Surgery*. 2003;**38**:331-335; discussion 331-335. DOI: 10.1053/jpsu.2003.50103

[49] Bhattacharyya NK, De A, Bera P, Mongal S, Chakraborty S, Bandopadhyay R. Ovarian tumors in pediatric age group—A clinicopathologic study of 10 years' cases in West Bengal, India. *The Indian Journal of Medical and Paediatric Oncology*. 2010;**31**:54

[50] Ovarian Cancer: Recognition and Initial Management | Guidance and Guidelines | NICE n.d. Available from: <https://www.nice.org.uk/Guidance/cg122> [Accessed: 03 August 2018]

[51] Vecchia CL, Levi F, Lucchini F, Negri E, Franceschi S. Descriptive epidemiology of ovarian cancer in Europe. *Gynecologic Oncology*. 1992;**46**:208-215. DOI: 10.1016/0090-8258(92)90257-J

[52] Klar M, Hasenburg A, Hasanov M, Hilpert F, Meier W, Pfisterer J, et al. Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials

of the AGO Study Group, GINECO and NSGO. *The European Journal of Cancer*. 1990, 2016;**66**:114-124. DOI: 10.1016/j.ejca.2016.07.014

[53] Murthy NS, Shalini S, Suman G, Pruthvish S, Mathew A. Changing trends in incidence of ovarian cancer—The Indian scenario. *The Asian Pacific Journal of Cancer Prevention*. 2009;**10**:1025-1030

[54] Saini SK. *Clinical Cancer Investigation Journal* n.d. Available from: <http://www.cci-j-online.org/article.asp?issn=2278-0513;year=2016;volume=5;issue=1;spage=20;epage=24;aulast=Saini> [Accessed: 03 August 2018]

[55] Basu P, De P, Mandal S, Ray K, Biswas J. Study of “patterns of care” of ovarian cancer patients in a specialized cancer institute in Kolkata, eastern India. *Indian Journal of Cancer*. 2009;**46**:28-33

[56] Jindal D, Sahasrabhojane M, Jindal M, D'Souza J. Epidemiology of epithelial ovarian cancer: A tertiary hospital based study in Goa, India. *International Journal of Reproduction, Contraception, Obstetrics and Gynecology*. 2017;**6**:2541. DOI: 10.18203/2320-1770.ijrcog20172348

[57] Malik IA. A prospective study of clinico-pathological features of epithelial ovarian cancer in Pakistan n.d.:8

[58] Mostafa MF, El-etreby N, Awad N. Retrospective analysis evaluating ovarian cancer cases presented at the clinical oncology department, Alexandria University. *Alexandria Journal of Medicine*. 2012;**48**:353-360. DOI: 10.1016/j.ajme.2012.07.001

[59] Zayyan MS, Ahmed SA, Oguntayo AO, Kolawole AO, Olasinde TA. Epidemiology of ovarian cancers in Zaria, northern Nigeria: A

10-year study. *International Journal of Women's Health*. 2017;**9**:855-860. DOI: 10.2147/IJWH.S130340

[60] Abuidris DO, Weng H-Y, Elhaj AM, Eltayeb EA, Elsanousi M, Ibnoof RS, et al. Incidence and survival rates of ovarian cancer in low-income women in Sudan. *Molecular and Clinical Oncology*. 2016;**5**:823-828. DOI: 10.3892/mco.2016.1068

[61] Akakpo PK, Derkyi-Kwarteng L, Gyasi RK, Quayson SE, Naporu S, Anim JT. A pathological and clinical study of 706 primary tumours of the ovary in the largest tertiary hospital in Ghana. *BMC Womens Health*. 2017;**17**:34. DOI: 10.1186/s12905-017-0389-8

[62] Gong T-T, Wu Q-J, Vogtmann E, Lin B, Wang Y-L. Age at menarche and risk of ovarian cancer: A meta-analysis of epidemiological studies. *International Journal of Cancer*. 2013;**132**:2894-2900. DOI: 10.1002/ijc.27952

[63] Adami HO, Hsieh CC, Lambe M, Trichopoulos D, Leon D, Persson I, et al. Parity, age at first childbirth, and risk of ovarian cancer. *Lancet (London, England)*. 1994;**344**:1250-1254

[64] Yancik R. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. *Cancer*. 1993;**71**:517-523

[65] Riman T, Nilsson S, Persson IR. Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. *Acta Obstetrica et Gynecologica Scandinavica*. 2004;**83**:783-795. DOI: 10.1111/j.0001-6349.2004.00550.x

[66] Riboli E. The European Prospective Investigation into Cancer and Nutrition (EPIC): Plans and progress. *The Journal of Nutrition*. 2001;**131**:170S-175S. DOI: 10.1093/jn/131.1.170S

[67] Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Ovarian tumors in a cohort of infertile women. *The New England Journal of Medicine*. 1994;**331**:771-776. DOI: 10.1056/NEJM199409223311204

[68] Jensen A, Sharif H, Frederiksen K, Kjær SK. Use of fertility drugs and risk of ovarian cancer: Danish population based cohort study. *BMJ*. 2009;**338**:580-583

[69] Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, et al. Infertility, fertility drugs, and ovarian cancer: A pooled analysis of case-control studies. *American Journal of Epidemiology*. 2002;**155**:217-224

[70] Mosgaard BJ, Lidegaard Ø, Kjaer SK, Schou G, Andersen AN. Infertility, fertility drugs, and invasive ovarian cancer: A case-control study. *Fertility and Sterility*. 1997;**67**:1005-1012. DOI: 10.1016/S0015-0282(97)81431-8

[71] Tomao F, Lo Russo G, Spinelli GP, Stati V, Prete AA, Prinzi N, et al. Fertility drugs, reproductive strategies and ovarian cancer risk. *Journal of Ovarian Research*. 2014;**7**:51. DOI: 10.1186/1757-2215-7-51

[72] Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M, et al. Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management. *Molecular Oncology*. 2009;**3**:97-137. DOI: 10.1016/j.molonc.2009.02.004

[73] Foulkes WD, Narod SA. Ovarian cancer risk and family history. *The Lancet*. 1997;**349**:878. DOI: 10.1016/S0140-6736(05)61782-5

[74] Kerlikowske K, Brown JS, Grady DG. Should women with familial ovarian cancer undergo prophylactic oophorectomy? *Obstetrics and Gynecology*. 1992;**80**:700-707

- [75] Family History of Ovarian Cancer - an overview | ScienceDirect Topics n.d. Available from: <https://www.sciencedirect.com/topics/medicine-and-dentistry/family-history-of-ovarian-cancer> [Accessed: 03 November 2018]
- [76] Soegaard M, Frederiksen K, Jensen A, Høgdall E, Høgdall C, Blaakaer J, et al. Risk of ovarian cancer in women with first-degree relatives with cancer. *Acta Obstetrica et Gynecologica Scandinavica*. 2009;**88**:449-456. DOI: 10.1080/00016340902807207
- [77] Toss A, Tomasello C, Razzaboni E, Contu G, Grandi G, Cagnacci A, et al. Hereditary ovarian cancer: Not only BRCA 1 and 2 genes. *BioMed Research International*. 2015. DOI: 10.1155/2015/341723
- [78] Robles-díaz L, Goldfrank DJ, Kauff ND, Robson M, Offit K. Hereditary ovarian cancer in Ashkenazi Jews. *Familial Cancer*. 2004;**3**:259-264. DOI: 10.1007/s10689-004-9552-0
- [79] Villella JA, Parmar M, Donohue K, Fahey C, Piver MS, Rodabaugh K. Role of prophylactic hysterectomy in patients at high risk for hereditary cancers. *Gynecologic Oncology*. 2006;**102**:475-479. DOI: 10.1016/j.ygyno.2006.01.006
- [80] Osman MA. Genetic cancer ovary. *Clinical Ovarian and Other Gynecologic Cancer*. 2014;**7**:1-7. DOI: 10.1016/j.cogc.2014.12.006
- [81] Lynch HT, Krush AJ. Heredity and adenocarcinoma of the colon. *Gastroenterology*. 1967;**53**:517-527
- [82] Watson P, Bützow R, Lynch HT, Mecklin JP, Järvinen HJ, Vasen HF, et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. *Gynecologic Oncology*. 2001;**82**:223-228. DOI: 10.1006/gyno.2001.6279
- [83] Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G, et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: A study of hereditary nonpolyposis colorectal cancer families. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 2001;**19**:4074-4080. DOI: 10.1200/JCO.2001.19.20.4074
- [84] Lynch HT, Boland CR, Gong G, Shaw TG, Lynch PM, Fodde R, et al. Phenotypic and genotypic heterogeneity in the Lynch syndrome: Diagnostic, surveillance and management implications. *European Journal of Human Genetics*. 2006;**14**:390-402. DOI: 10.1038/sj.ejhg.5201584
- [85] Watson P, Vasen HFA, Mecklin J-P, Bernstein I, Aarnio M, Järvinen HJ, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. *The International Journal of Cancer*. 2008;**123**:444-449. DOI: 10.1002/ijc.23508
- [86] Liu J, Albarracin CT, Chang K-H, Thompson-Lanza JA, Zheng W, Gershenson DM, et al. Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. *Modern Pathology*. 2004;**17**:75-80. DOI: 10.1038/sj.modpathol.3800017
- [87] Chui MH, Gilks CB, Cooper K, Clarke BA. Identifying Lynch syndrome in patients with ovarian carcinoma: The significance of tumor subtype. *Advances in Anatomic Pathology*. 2013;**20**:378-386. DOI: 10.1097/PAP.0b013e3182a92cf8
- [88] Beyond Li-Fraumeni syndrome: Clinical characteristics of families with p53 germline mutations. *Journal of Clinical Oncology*. n.d. 26(15_suppl). Available from: http://ascopubs.org/doi/abs/10.1200/jco.2008.26.15_suppl.11031 [Accessed: 12 November 2018]

- [89] Hisada M, Garber JE, Fung CY, Fraumeni JF, Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. *Journal of the National Cancer Institute*. 1998;**90**:606-611
- [90] Varley JM, Evans DG, Birch JM. Li-Fraumeni syndrome—A molecular and clinical review. *British Journal of Cancer*. 1997;**76**:1-14
- [91] Oral and Maxillofacial Pathology. 3rd ed. n.d. Available from: <https://www.elsevier.com/books/oral-and-maxillofacial-pathology/neville/978-1-4160-3435-3> [Accessed: 13 November 2018]
- [92] Banno K, Kisu I, Yanokura M, Masuda K, Ueki A, Kobayashi Y, et al. Hereditary gynecological tumors associated with Peutz-Jeghers syndrome (review). *Oncology Letters*. 2013;**6**:1184-1188. DOI: 10.3892/ol.2013.1527
- [93] Papp J, Kovacs ME, Solyom S, Kasler M, Børresen-Dale A-L, Olah E. High prevalence of germline STK11 mutations in Hungarian Peutz-Jeghers syndrome patients. *BMC Medical Genetics*. 2010;**11**:169. DOI: 10.1186/1471-2350-11-169
- [94] Prat J, Ribé A, Gallardo A. Hereditary ovarian cancer. *Human Pathology*. 2005;**36**:861-870. DOI: 10.1016/j.humpath.2005.06.006
- [95] Fackenthal JD, Zhang J, Zhang B, Zheng Y, Hagos F, Burrill DR, et al. High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. *International Journal of Cancer*. 2012;**131**:1114-1123. DOI: 10.1002/ijc.27326
- [96] Schmolz G. The carcinogenic effect of asbestos. *Öffentliche Gesundheitswesen*. 1989;**51**:614-620
- [97] Barrett JC, Lamb PW, Wiseman RW. Multiple mechanisms for the carcinogenic effects of asbestos and other mineral fibers. *Environmental Health Perspectives*. 1989;**81**:81-89
- [98] Cramer DW, Vitonis AF, Terry KL, Welch WR, Titus LJ. The association between talc use and ovarian cancer: A retrospective case-control study in Two US States. *Epidemiology (Cambridge, Mass.)*. 2016;**27**:334-346. DOI: 10.1097/EDE.0000000000000434
- [99] Cramer DW, Welch WR, Berkowitz RS, Godleski JJ. Presence of talc in pelvic lymph nodes of a woman with ovarian cancer and long-term genital exposure to cosmetic talc. *Obstetrics and Gynecology*. 2007;**110**:498-501. DOI: 10.1097/01.AOG.0000262902.80861.a0
- [100] IARC Monographs Volume 100C Asbestos (Chrysotile, Amosite, Crocidolite, Tremolite, Actinolite and Anthophyllite) – IARC n.d. Available from: <https://monographs.iarc.fr/iarc-monographs-volume-100c-asbestos-chrysotile-amosite-crocidolite-tremolite-actinolite-and-anthophyllite/> [Accessed: 13 November 2018]
- [101] Asbestos and Cancer Risk n.d. Available from: <https://www.cancer.org/cancer/cancer-causes/asbestos.html> [Accessed: 13 November 2018]
- [102] Muscat JE, Huncharek MS. Perineal talc use and ovarian cancer: A critical review. *The European Journal of Cancer Prevention*. 2008;**17**:139-146. DOI: 10.1097/CEJ.0b013e32811080ef
- [103] Gertig DM, Hunter DJ, Cramer DW, Colditz GA, Speizer FE, Willett WC, et al. Prospective study of talc use and ovarian cancer. *The Journal of the National Cancer Institute*. 2000;**92**:249-252. DOI: 10.1093/jnci/92.3.249
- [104] Berge W, Mundt K, Luu H, Boffetta P. Genital use of talc and risk of ovarian cancer: A meta-analysis. *European Journal of Cancer*

Prevention. 2018;**27**:248. DOI: 10.1097/CEJ.0000000000000340

[105] Kennerly M, Esq. The Science Connecting Talcum Powder And Ovarian Cancer. Litig Trial Lawyer Blog 2016. Available from: <https://www.litigationandtrial.com/2016/05/articles/attorney/consumer-protection/talcum-powder-ovarian-cancer/> [Accessed: 13 November 2018]

[106] Zhang M, Yang ZY, Binns CW, Lee AH. Diet and ovarian cancer risk: A case-control study in China. *British Journal of Cancer*. 2002;**86**:712-717. DOI: 10.1038/sj.bjc.6600085

[107] Plagens-Rotman K, Chmaj-Wierzchowska K, Pięta B, Bojar I. Modifiable lifestyle factors and ovarian cancer incidence in women. *Annals of Agricultural and Environmental Medicine*. 2018;**25**:36-40. DOI: 10.5604/12321966.1233565

[108] Schulz M, Lahmann PH, Boeing H, Hoffmann K, Allen N, Key TJA, et al. Fruit and vegetable consumption and risk of epithelial ovarian cancer: The European prospective investigation into cancer and nutrition. *Cancer Epidemiology, Biomarkers and Prevention*. 2005;**14**:2531-2535. DOI: 10.1158/1055-9965.EPI-05-0159

[109] Han B, Li X, Yu T. Cruciferous vegetables consumption and the risk of ovarian cancer: A meta-analysis of observational studies. *Diagnostic Pathology*. 2014;**9**:7. DOI: 10.1186/1746-1596-9-7

[110] Tang L, Lee AH, Su D, Binns CW. Fruit and vegetable consumption associated with reduced risk of epithelial ovarian cancer in southern Chinese women. *Gynecologic Oncology*. 2014;**132**:241-247. DOI: 10.1016/j.ygyno.2013.10.020

[111] Pan SY, Ugnat A-M, Mao Y, Wen SW, Johnson KC. A case-control

study of diet and the risk of ovarian cancer. *Cancer Epidemiology, Biomarkers and Prevention*. 2004;**8**

[112] McCann SE, Freudenheim JL, Marshall JR, Graham S. Risk of human ovarian cancer is related to dietary intake of selected nutrients, phytochemicals and food groups. *The Journal of Nutrition*. 2003;**133**:1937-1942. DOI: 10.1093/jn/133.6.1937

[113] Genkinger JM, Hunter DJ, Spiegelman D, Anderson KE, Arslan A, Beeson WL, et al. Dairy products and ovarian cancer: A pooled analysis of 12 cohort studies. *Cancer Epidemiology, Biomarkers and Prevention*. 2006;**15**:364-372. DOI: 10.1158/1055-9965.EPI-05-0484

[114] Mommers M, Schouten LJ, Goldbohm RA, van den Brandt PA. Dairy consumption and ovarian cancer risk in the Netherlands cohort study on diet and cancer. *British Journal of Cancer*. 2006;**94**:165-170. DOI: 10.1038/sj.bjc.6602890

[115] Faber MT, Jensen A, Søgaaard M, Høgdall E, Høgdall C, Blaakaer J, et al. Use of dairy products, lactose, and calcium and risk of ovarian cancer—Results from a Danish case-control study. *Acta Oncologica (Stockholm, Sweden)*. 2012;**51**:454-464. DOI: 10.3109/0284186X.2011.636754

[116] Merritt MA, Cramer DW, Vitonis AF, Titus LJ, Terry KL. Dairy foods and nutrients in relation to risk of ovarian cancer and major histological subtypes. *International Journal of Cancer*. 2013;**132**:1114-1124. DOI: 10.1002/ijc.27701

[117] Huncharek M, Kupelnick B. Dietary fat intake and risk of epithelial ovarian cancer: A meta-analysis of 6,689 subjects from 8 observational studies. *Nutrition and Cancer*. 2001;**40**:87-91. DOI: 10.1207/S15327914NC402_2

- [118] Qiu W, Lu H, Qi Y, Wang X. Dietary fat intake and ovarian cancer risk: A meta-analysis of epidemiological studies. *Oncotarget*. 2016;7:37390-37406. DOI: 10.18632/oncotarget.8940
- [119] Bertone ER, Rosner BA, Hunter DJ, Stampfer MJ, Speizer FE, Colditz GA, et al. Dietary fat intake and ovarian cancer in a cohort of US women. *American Journal of Epidemiology*. 2002;156:22-31. DOI: 10.1093/aje/kwf008
- [120] Keum N, Lee DH, Marchand N, Oh H, Liu H, Aune D, et al. Egg intake and cancers of the breast, ovary and prostate: A dose-response meta-analysis of prospective observational studies. *The British Journal of Nutrition*. 2015;114:1099-1107. DOI: 10.1017/S0007114515002135
- [121] Risch HA, Jain M, Marrett LD, Howe GR. Dietary fat intake and risk of epithelial ovarian cancer. *The Journal of the National Cancer Institute*. 1994;86:1409-1415. DOI: 10.1093/jnci/86.18.1409
- [122] Gilsing AM, Weijenberg MP, Goldbohm RA, van den Brandt PA, Schouten LJ. Consumption of dietary fat and meat and risk of ovarian cancer in the Netherlands cohort study. *The American Journal of Clinical Nutrition*. 2011;93:118-126. DOI: 10.3945/ajcn.2010.29888
- [123] Meat consumption and cancer risk: A critical review of published meta-analyses. *Critical Reviews in Oncology/Hematology*. 2016;97:1-14. DOI: 10.1016/j.critrevonc.2015.11.008
- [124] Kushi LH, Mink PJ, Folsom AR, Anderson KE, Zheng W, Lazovich D, et al. Prospective study of diet and ovarian cancer. *American Journal of Epidemiology*. 1999;149:21-31
- [125] Wallin A, Orsini N, Wolk A. Red and processed meat consumption and risk of ovarian cancer: A dose-response meta-analysis of prospective studies. *British Journal of Cancer*. 2011;104:1196-1201. DOI: 10.1038/bjc.2011.49
- [126] Kolahdooz F, van der Pols JC, Bain CJ, Marks GC, Hughes MC, Whiteman DC, et al. Meat, fish, and ovarian cancer risk: Results from 2 Australian case-control studies, a systematic review, and meta-analysis. *The American Journal of Clinical Nutrition*. 2010;91:1752-1763. DOI: 10.3945/ajcn.2009.28415
- [127] Chang ET, Canchola AJ, Lee VS, Clarke CA, Purdie DM, Reynolds P, et al. Wine and other alcohol consumption and risk of ovarian cancer in the California Teachers Study cohort. *Cancer Causes Control*. 2007;18:91-103. DOI: 10.1007/s10552-006-0083-x
- [128] Schouten LJ, Zeegers MPA, Goldbohm RA, van den Brandt PA. Alcohol and ovarian cancer risk: Results from the Netherlands cohort study. *Cancer Causes and Control*. 2004;15:201-209. DOI: 10.1023/B:CACO.0000019512.71560.2b
- [129] Gwinn ML, Webster LA, Lee NC, Layde PM, Rubin GL. Alcohol consumption and ovarian cancer risk. *American Journal of Epidemiology*. 1986;123:759-766. DOI: 10.1093/oxfordjournals.aje.a114304
- [130] Webb PM, Purdie DM, Bain CJ, Green AC. Alcohol, wine, and risk of epithelial ovarian cancer. *Cancer Epidemiology, Biomarkers and Prevention*. 2004;13:592-599
- [131] Gosvig CF, Kjaer SK, Blaakær J, Høgdall E, Høgdall C, Jensen A. Coffee, tea, and caffeine consumption and risk of epithelial ovarian cancer and borderline ovarian tumors: Results from a Danish case-control study. *Acta Oncologica*. 2015;54:1144-1151. DOI: 10.3109/0284186X.2014.1001035

- [132] Tworoger SS, Gertig DM, Gates MA, Hecht JL, Hankinson SE. Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer. *Cancer*. 2008;**112**:1169-1177. DOI: 10.1002/cncr.23275
- [133] Huncharek M, Klassen H, Kupelnick B. Dietary beta-carotene intake and the risk of epithelial ovarian cancer: A meta-analysis of 3,782 subjects from five observational studies. *Vivo Athens Greece*. 2001;**15**:339-343
- [134] Terry PD, Qin B, Camacho F, Moorman PG, Alberg AJ, Barnholtz-Sloan JS, et al. Supplemental selenium may decrease ovarian cancer risk in African-American women. *The Journal of Nutrition*. 2017;**147**:621-627. DOI: 10.3945/jn.116.243279
- [135] Dennert G, Zwahlen M, Brinkman M, Vinceti M, Zeegers MPA, Horneber M. Selenium for preventing cancer. *Cochrane Database of Systematic Reviews*. 2011:CD005195. DOI: 10.1002/14651858.CD005195.pub2
- [136] Ong J-S, Cuellar-Partida G, Lu Y, Fasching PA, Hein A, Burghaus S, et al. Association of vitamin D levels and risk of ovarian cancer: A Mendelian randomization study. *International Journal of Epidemiology*. 2016;**45**:1619-1630. DOI: 10.1093/ije/dyw207
- [137] Guo H, Guo J, Xie W, Yuan L, Sheng X. The role of vitamin D in ovarian cancer: Epidemiology, molecular mechanism and prevention. *Journal of Ovarian Research*. 2018;**11**. DOI: 10.1186/s13048-018-0443-7
- [138] Loeb LA. Tobacco causes human cancers—A concept founded on epidemiology and an insightful experiment now requires translation worldwide. *Cancer Research*. 2016;**76**:765-766. DOI: 10.1158/0008-5472.CAN-16-0149
- [139] Marchbanks PA, Wilson H, Bastos E, Cramer DW, Schildkraut JM, Peterson HB. Cigarette smoking and epithelial ovarian cancer by histologic type. *Obstetrics and Gynecology*. 2000;**95**:255-260
- [140] Licaj I, Jacobsen BK, Selmer RM, Maskarinec G, Weiderpass E, Gram IT. Smoking and risk of ovarian cancer by histological subtypes: An analysis among 300 000 Norwegian women. *British Journal of Cancer*. 2017;**116**:270-276. DOI: 10.1038/bjc.2016.418
- [141] Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L. Cigarette smoking and increased risk of mucinous epithelial ovarian cancer. *American Journal of Epidemiology*. 2004;**159**:133-139. DOI: 10.1093/aje/kwh015
- [142] Faber MT, Kjær SK, Dehlendorff C, Chang-Claude J, Andersen KK, Høgdall E, et al. Cigarette smoking and risk of ovarian cancer: A pooled analysis of 21 case–control studies. *Cancer Causes Control CCC*. 2013;**24**. DOI: 10.1007/s10552-013-0174-4
- [143] Gram IT, Lukanova A, Brill I, Braaten T, Lund E, Lundin E, et al. Cigarette smoking and risk of histological subtypes of epithelial ovarian cancer in the EPIC cohort study. *International Journal of Cancer*. 2012;**130**:2204-2210. DOI: 10.1002/ijc.26235
- [144] Ovarian cancer and smoking: individual participant meta-analysis including 28 114 women with ovarian cancer from 51 epidemiological studies. *The Lancet Oncology*. 2012;**13**:946-956. DOI: 10.1016/S1470-2045(12)70322-4
- [145] Modugno F, Ness RB, Cottreau CM. Cigarette smoking and the risk of mucinous and nonmucinous epithelial ovarian cancer. *Epidemiology (Cambridge, Mass.)*. 2002;**13**:467-471
- [146] Terry PD, Miller AB, Jones JG, Rohan TE. Cigarette smoking and the

risk of invasive epithelial ovarian cancer in a prospective cohort study. *European Journal of Cancer* (Oxford, England: 1990). 2003;**39**:1157-1164

[147] Sayasneh A, Tsivos D, Crawford R. Endometriosis and ovarian cancer: A systematic review. *ISRN Obstetrics and Gynecology*. 2011;**2011**. DOI: 10.5402/2011/140310

[148] Zafrakas M, Grimbizis G, Timologou A, Tarlatzis BC. Endometriosis and ovarian cancer risk: A systematic review of epidemiological studies. *Frontiers in Surgery*. 2014;**1**. DOI: 10.3389/fsurg.2014.00014

[149] Brinton LA, Gridley G, Persson I, Baron J, Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. *American Journal of Obstetrics and Gynecology*. 1997;**176**:572-579

[150] Vercellini P, Somigliana E, Buggio L, Bolis G, Fedele L. Endometriosis and ovarian cancer. *The Lancet Oncology*. 2012;**13**:e188-e189. DOI: 10.1016/S1470-2045(12)70198-5

[151] Brilhante AVM, Augusto KL, Portela MC, Sucupira LCG, Oliveira LAF, Pouchaim AJMV, et al. Endometriosis and ovarian cancer: An integrative review (endometriosis and ovarian cancer). *Asian Pacific Journal of Cancer Prevention*. 2017;**18**:11-16. DOI: 10.22034/APJCP.2017.18.1.11

[152] The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertility and Sterility*. 2004;**81**:19-25. DOI: 10.1016/j.fertnstert.2003.10.004

[153] Schildkraut J. Epithelial ovarian cancer risk among women with

polycystic ovary syndrome. *Obstetrics and Gynecology*. 1996;**88**:554-559. DOI: 10.1016/0029-7844(96)00226-8

[154] Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): Arguably the most common endocrinopathy is associated with significant morbidity in women. *The Journal of Clinical Endocrinology and Metabolism*. 1999;**84**:1897-1899. DOI: 10.1210/jcem.84.6.5803

[155] Harris HR, Terry KL. Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: A systematic review. *Fertility Research and Practice*. 2016;**2**:14. DOI: 10.1186/s40738-016-0029-2

[156] Galazis N, Olaleye O, Haoula Z, Layfield R, Atiomo W. Proteomic biomarkers for ovarian cancer risk in women with polycystic ovary syndrome: A systematic review and biomarker database integration. *Fertility and Sterility*. 2012;**98**:1590-1601.e1. DOI: 10.1016/j.fertnstert.2012.08.002

[157] Rasmussen CB, Kjaer SK, Albieri V, Bandera EV, Doherty JA, Høgdall E, et al. Pelvic inflammatory disease and the risk of ovarian cancer and borderline ovarian tumors: A pooled analysis of 13 case-control studies. *American Journal of Epidemiology*. 2017;**185**:8-20. DOI: 10.1093/aje/kww161

[158] Zhou Z, Zeng F, Yuan J, Tang J, Colditz GA, Tworoger SS, et al. Pelvic inflammatory disease and the risk of ovarian cancer: A meta-analysis. *Cancer Causes Control*. 2017;**28**:415-428. DOI: 10.1007/s10552-017-0873-3

[159] Parazzini F, Vecchia CL, Negri E, Moroni S, Dal Pino D, Fedele L. Pelvic inflammatory disease and risk of ovarian cancer. *Cancer Epidemiology, Biomarkers and Prevention*. 1996;**5**:667-669

- [160] Merritt MA, Green AC, Nagle CM, Webb PM, Australian Cancer study (ovarian Cancer), Australian ovarian Cancer study group. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. *International Journal of Cancer*. 2008;**122**:170-176. DOI: 10.1002/ijc.23017
- [161] Greiser CM, Greiser EM, Dören M. Menopausal hormone therapy and risk of ovarian cancer: Systematic review and meta-analysis. *Human Reproduction Update*. 2007;**13**:453-463. DOI: 10.1093/humupd/dmm012
- [162] Danforth KN, Tworoger SS, Hecht JL, Rosner BA, Colditz GA, Hankinson SE. A prospective study of postmenopausal hormone use and ovarian cancer risk. *British Journal of Cancer*. 2007;**96**:151-156. DOI: 10.1038/sj.bjc.6603527
- [163] Beral V, Million Women Study Collaborators, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the million women study. *Lancet* (London, England). 2007;**369**:1703-1710. DOI: 10.1016/S0140-6736(07)60534-0
- [164] Lee AW, Ness RB, Roman LD, Terry KL, Schildkraut JM, Chang-Claude J, et al. Association between menopausal estrogen-only therapy and ovarian carcinoma Risk. *Obstetrics and Gynecology*. 2016;**127**:828-836. DOI: 10.1097/AOG.0000000000001387
- [165] Hormone Replacement Therapy May Increase Ovarian Cancer Risk. *Medscape* n.d. Available from: <http://www.medscape.com/viewarticle/839758> [Accessed: 01 December 2018]
- [166] Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, et al. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. *Lancet* (London, England). 2015;**385**:1835-1842. DOI: 10.1016/S0140-6736(14)61687-1
- [167] Olsen CM, Green AC, Whiteman DC, Sadeghi S, Kolahdooz F, Webb PM. Obesity and the risk of epithelial ovarian cancer: A systematic review and meta-analysis. *European Journal of Cancer*. 2007;**43**:690-709. DOI: 10.1016/j.ejca.2006.11.010
- [168] Crosbie EJ, Zwahlen M, Kitchener HC, Egger M, Renehan AG. Body mass index, hormone replacement therapy, and endometrial cancer risk: A meta-analysis. *Cancer Epidemiology, Biomarkers and Prevention*. 2010;**19**:3119-3130. DOI: 10.1158/1055-9965.EPI-10-0832
- [169] Olsen CM, Nagle CM, Whiteman DC, Ness R, Pearce CL, Pike MC, et al. Obesity and risk of ovarian cancer subtypes: Evidence from the Ovarian Cancer Association Consortium. *Endocrine-Related Cancer*. 2013;**20**:251-262. DOI: 10.1530/ERC-12-0395
- [170] Tworoger SS, Huang T. Obesity and ovarian cancer. *Recent Results in Cancer Research*. 2016;**208**:155-176. DOI: 10.1007/978-3-319-42542-9_9
- [171] Jochem C, Schlecht I, Leitzmann M. Epidemiologic relationship between obesity and ovarian cancer. In: Berger NA, Klopp AH, Lu KH, editors. *Focus on Gynecologic Malignancies*. Vol. 13. Cham: Springer International Publishing; 2018. pp. 21-30. DOI: 10.1007/978-3-319-63483-8_2
- [172] Nagle CM, Dixon SC, Jensen A, Kjaer SK, Modugno F, deFazio A, et al. Obesity and survival among women with ovarian cancer: Results from the Ovarian Cancer Association Consortium. *British Journal of Cancer*.

2015;**113**:817-826. DOI: 10.1038/bjc.2015.245

[173] Foong KW, Bolton H. Obesity and ovarian cancer risk: A systematic review. *Post Reproductive Health*. 2017;**23**:183-198. DOI: 10.1177/2053369117709225

[174] Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV, et al. Ovarian cancer risk factors by histologic subtype: An analysis from the ovarian Cancer Cohort Consortium. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 2016;**34**:2888-2898. DOI: 10.1200/JCO.2016.66.8178

[175] Luan N-N, Wu Q-J, Gong T-T, Vogtman E, Wang Y-L, Lin B. Breastfeeding and ovarian cancer risk: A meta-analysis of epidemiologic studies. *The American Journal of Clinical Nutrition*. 2013;**98**:1020-1031. DOI: 10.3945/ajcn.113.062794

[176] McNeilly AS. Lactational control of reproduction. *Reproduction, Fertility, and Development*. 2001;**13**:583-590

[177] Stadel BV. The etiology and prevention of ovarian cancer. *American Journal of Obstetrics and Gynecology*. 1975;**123**:772-774. DOI: 10.1016/0002-9378(75)90509-8

[178] Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer and oral contraceptives: Collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. *Lancet (London, England)*. 2008;**371**:303-314. DOI: 10.1016/S0140-6736(08)60167-1

[179] Why do Oral Contraceptives Prevent Ovarian Cancer? - Full Text View - ClinicalTrials.gov n.d. Available from: [https://clinicaltrials.gov/ct2/](https://clinicaltrials.gov/ct2/show/NCT02155777)

[show/NCT02155777](https://clinicaltrials.gov/ct2/show/NCT02155777) [Accessed: 19 November 2018]

[180] Tsilidis KK, Allen NE, Key TJ, Dossus L, Lukanova A, Bakken K, et al. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. 2011;**1442**. DOI: 10.1038/bjc.2011.371

[181] Bosetti C, Negri E, Trichopoulos D, Franceschi S, Beral V, Tzonou A, et al. Long-term effects of oral contraceptives on ovarian cancer risk. *International Journal of Cancer*. 2002;**102**:262-265. DOI: 10.1002/ijc.10696

[182] Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: A systematic review and meta-analysis. *Journal of Clinical Oncology*. 2013;**31**:4188-4198. DOI: 10.1200/JCO.2013.48.9021

[183] Ferris JS, Daly MB, Buys SS, Genkinger JM, Liao Y, Terry MB. Oral contraceptive and reproductive risk factors for ovarian cancer within sisters in the breast cancer family registry. *British Journal of Cancer*. 2014;**110**:1074-1080. DOI: 10.1038/bjc.2013.803

[184] Rice MS, Hankinson SE, Tworoger SS. Tubal ligation, hysterectomy, unilateral oophorectomy, and risk of ovarian cancer in the nurses' health studies. *Fertility and Sterility*. 2014;**102**:192-198.e3. DOI: 10.1016/j.fertnstert.2014.03.041

[185] Chan JK, Urban R, Capra AM, Jacoby V, Osann K, Whittemore A, et al. Ovarian cancer rates after hysterectomy with and without salpingo-oophorectomy. *Obstetrics and Gynecology*. 2014;**123**:65-72. DOI: 10.1097/AOG.0000000000000061

[186] Narod SA, Sun P, Ghadirian P, Lynch H, Isaacs C, Garber J, et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: A case-control study. *The Lancet*. 2001;**357**:1467-1470. DOI: 10.1016/S0140-6736(00)04642-0

[187] Gaitskell K, Green J, Pirie K, Reeves G. Tubal ligation and ovarian cancer risk in a large cohort: Substantial variation by histological type. *International Journal of Cancer*. 2016;**138**:1076-1084. DOI: 10.1002/ijc.29856

[188] Hannan LM, Leitzmann MF, Lacey JV, Colbert LH, Albanes D, Schatzkin A, et al. Physical activity and risk of ovarian cancer: A prospective cohort study in the United States. *Cancer Epidemiology and Prevention Biomarkers*. 2004;**13**:765-770

[189] Moorman PG, Jones LW, Akushevich L, Schildkraut JM. Recreational physical activity and ovarian cancer risk and survival. *Annals of Epidemiology*. 2011;**21**:178-187. DOI: 10.1016/j.annepidem.2010.10.014

[190] Tavani A, Gallus S, La Vecchia C, Dal Maso L, Negri E, Pelucchi C, et al. Physical activity and risk of ovarian cancer: An Italian case-control study. *International Journal of Cancer*. 2001;**91**:407-411

[191] Pan SY, Ugnat A-M, Mao Y. Physical activity and the risk of ovarian cancer: A case-control study in Canada. *International Journal of Cancer*. 2005;**117**:300-307. DOI: 10.1002/ijc.21157